Abstract
The meaning and purpose behind a generic, or non-proprietary, name is elusive, even to those well entrenched in the medical profession and pharmaceutical industry. This paper intends to define generic names, explain their purpose and the global challenges they pose to manufacturers, provide some insight to their development – citing the US development process — and identify how the non-proprietary name can support marketing opportunities.
Get full access to this article
View all access options for this article.
References
1.
(2002 ) ‘USP Dictionary of USAN and International Drug Names’ , pp. 7 –8 and Appendix VII, pp. 1225 –1235 .
2.‘Guidance on INN’ (online at http://www.who.int/medicines/organization/qsm/activities/qualityassurance/inn/innguide.shtml).
3.US Food and Drug Administration, Center for Drug Evaluation and Research , ‘What are Generic Drugs?’ (online at http://www.fda.gov/cder/ogd/andintroduction).
4.
Interview with Robert E. Lee, Jr, Trademark Counsel, Eli Lilly, 25th February, 2003 .
5.World Trade Organization , ‘Intellectual Property: Protection and Enforcement’ in ‘Trading into the Future; The Introduction to the WTO’ , www.wto.org.
6.
(2003 ) ‘The battle for generics starts early’ , International Herald Tribune , 1st-2nd March, p. 18 .
7.World Trade Organization , ‘The Uruguay Round’ (online at http://www.wto.org/english/thewto_e/whatis_e/tif_e/fact5_e.htm).
8.Interview with Stephanie Shubat , USAN Council Assistant Secretary, 27th March, 2003 .
9.WHO Drug Information (online at www.who.int/druginformation).
10.USAN Council (1999 ) ‘The name game: A look at the naming of drugs and the group responsible’ .
11.
(2002 ) ‘Prilosec OTC launch delayed’ Pharmafocus news story, 2nd November.